Compare EBON & BFRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EBON | BFRI |
|---|---|---|
| Founded | 2010 | 1997 |
| Country | China | United States |
| Employees | N/A | 94 |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.0M | 13.2M |
| IPO Year | 2020 | N/A |
| Metric | EBON | BFRI |
|---|---|---|
| Price | $2.16 | $1.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.75 |
| AVG Volume (30 Days) | 12.5K | ★ 381.2K |
| Earning Date | 04-24-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $14.36 |
| Revenue Next Year | N/A | $16.98 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.61 | $0.57 |
| 52 Week High | $5.90 | $1.21 |
| Indicator | EBON | BFRI |
|---|---|---|
| Relative Strength Index (RSI) | 45.22 | 52.43 |
| Support Level | $1.74 | $0.77 |
| Resistance Level | $2.76 | $1.14 |
| Average True Range (ATR) | 0.23 | 0.09 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 44.12 | 48.73 |
Ebang International Holdings Inc is engaged in blockchain technology and fintech, with activities also extending to the solar industry, supported by its application-specific integrated circuit (ASIC) chip designs. The Company's business mainly includes the sale of bitcoin mining machines and related accessories, telecommunication products, solar and battery storage products, cryptocurrency exchange services, cross-border payment and foreign exchange services, SaaS data visualization and analytics solutions, and rental services. It generates the majority of its revenue from cross-border payment and foreign exchange services, with its operations mainly in mainland China and Australia, which contribute the maximum revenue.
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions. The company's revenues are derived from within the United States and, therefore, no other geographical segments.